9 May - 10 May 2023

Kinase 2023: 10th SCI / RSC Symposium on Kinase Inhibitor Design

Organised by:

SCI's Fine Chemicals Group and RSC’s Biological and Medicinal Chemistry Sector

SCI, London, UK

Register for this event

Prices start from £295.00

Early bird offer ends 28 March 2023

Synopsis

With more than 70 FDA-approved small molecules, the field of kinase inhibition continues to attract significant investment from the drug discovery and development community. The 10th SCI/RSC symposium on kinases will encompass plenary lectures on emergent topics and case studies of ongoing programmes as well as successful past programmes. A range of topics including new screening approaches, brain penetrant kinase inhibitors, induced protein degradation, allosteric inhibitors and kinase inhibition for immuno-oncology will be covered, along with views and perspectives on the future of kinase inhibitor research.


Attendees

This event is aimed at all scientists interested in furthering their knowledge of kinases. It will also have wider appeal to members of the drug discovery community eager to understand how enzyme inhibitor programmes are approached and executed across the pharmaceutical industry.

This event will bring together industrial and academic experts representing many of the leading institutions in kinase drug discovery, to discuss a selection of new and emerging topics within the fields of kinase therapeutics for oncology and non-oncology therapies, and foster discussions within the wider industry through networking events such as poster sessions and industrial exhibitions.


Call for Posters

Abstracts covering any aspect of Kinase inhibitor research are invited for poster presentation.

Abstracts (300 words max.) should indicate a poster title and authors. Please send your abstract by email to conferences@soci.org with the subject "Kinase 2023 - poster abstract" by Friday 7 April. Download an abstract template hereThere may also be an opportunity to do an oral presentation depending on programme availability.


Student Bursaries

A limited number of student bursaries are available to registered participants, as a contribution to the cost of registration fees, travel and accommodation. The closing date for applications is Friday 7 April 2023, to apply for a bursary, please email conferences@soci.org.


Confirmed speakers

Keynote lecture: Title to be confirmed

Amit Choudhary, Broad Institute, USA

The discovery of new inhibitors of cKIT for the treatment of GIST

Andreas Blum, Merck KGaA, Germany

Discovery and optimisation of potent, slow-dissociating inhaled PI4KB inhibitors

Sophie Bertrand, GSK, UK

Focal adhesion kinase: mechanistic insights as guide for allosteric targeting

Daniel Lietha, CIB-CSIC, Spain

Development of MAP4K4 inhibitors for the suppression of cardiac muscle cell death

Rehan Aqil, Domainex, UK

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer

Antonio Ricci, Roche, Switzerland

The importance of conformation in the structure-based design of selective CaMK1 inhibitors

Sam Butterworth, University of Manchester, UK

Brain penetrant protein kinase inhibitors as potent modulators of TDP-43: a new hope for ALS therapy?

Ana Martinez, CSIC, Spain

Optimisation of Mer/Axl kinase inhibitors for immuno-oncology

William McCoull, AstraZeneca, UK

Inhibition of TYK2 via the pseudokinase: the discovery of deucravacitinib

Ryan Moslin, Bristol-Myers Squibb, USA

Structure-based optimisation of CNS penetrant MSK-1 inhibitors

Anne Valade, UCB, Belgium


Sponsorship

For further information and prices, please email conferences@soci.org.


Speakers

Antonio Ricci

Roche

Antonio Ricci is a Principal Scientist and Group Leader in the Medicinal Chemistry department at F. Hoffmann- La Roche in Basel (CH). He joined the Medicinal Chemistry department in 2003 as research associate and moved through different ranks up to the position of a research scientist. Antonio is a passionate drug hunter with major contributions to late stage projects, e.g. the discovery of Basimglurant, a promising novel medicine for psychiatric diseases. His recent research is focusing on oncology, in particular cancer cell targeted therapies.

Daniel Lietha

CIB-CSIC

Daniel Lietha is a structural biologist interested in kinase structure and regulation. He did his postdoctoral work with Prof. M.J. Eck at the Dana-Faber Cancer Institute, Harvard Medical School (USA). In 2009 he started his independent research, first at the Spanish National Cancer Research Centre (CNIO, Madrid) and since 2019 at the Margarita Salas Center for Biological Research (CIB-CSIC, Madrid). His research focuses on understanding the structure and mechanisms of signalling complexes involved in cell migration and cancer invasion. He further utilizes structural and mechanistic insights for allosteric drug discovery aiming to target native regulatory sites with high specificity.

Ryan Moslin

Bristol Myers Squibb

Ryan joined Bristol Myers Squibb (BMS) in 2010 where he was given an ambitious side project looking at inhibiting TYK2 via the pseudokinase by his supervisor and eventual mentor David Weinstein. Said project culminated in their invention of the first ever clinical agent to target a pseudokinase domain (deucravacitinib). For this invention Ryan and the TYK2 pseudokinase chemistry team were recognized with the 2019 Thomas A. Edison Patent award. Ryan was also recognized as a 2020 ACS Young (Industrial) Investigator and has served as a researcher advocate for PhRMA (GoBoldly) and as a patient (psoriasis) advocate within BMS.

Sam Butterworth

University of Manchester

Biography: Sam joined the University of Manchester as a Senior Lecturer in Medicinal Chemistry in November 2016. Prior to this he worked at the University of Birmingham from 2013 and at AstraZeneca from 2005-2013. During this time he has been accountable for chemistry strategy and delivery for all phases of drug discovery projects from target review and hit generation, through to lead optimisation and pre-clinical development. His work at AstraZeneca led to the development of a targeted anti-cancer agent osimertinib that was approved by the FDA in November 2015, and along with his colleagues Sam has been recognised for this work through the 2017 RSC Malcolm Campbell Award and the 2018 ACS Heroes of Chemistry award.

Sophie Bertrand

GSK

Sophie is a team leader in the Medicinal Chemistry department in Stevenage (UK). She joined GSK in 2006, following her graduation from CPE Lyon in France with a Masters degree in Chemical Sciences and Engineering. In 2011, she entered the GSK/Strathclyde PhD programme under the supervision of Dr Craig Jamieson, from which she graduated in 2015. For the past 17 years, Sophie has worked on a variety of targets across multiple disease areas, from fragment-based drug discovery approaches all the way to late lead optimisation. She led the PI4KB medicinal chemistry team that delivered a first in class inhaled clinical candidate for the prevention of rhinoviral-driven exacerbations in respiratory diseases.


Programme

The programme will be confirmed in due course.


Venue and Contact

SCI

14/15 Belgrave Square
London
SW1X 8PS

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Fees
Before early bird - ends 28 March 2023
SCI/RSC* Member - £295
Non-member - £370
SCI/RSC* Student member - £135
After early bird
SCI/RSC* Member - £345
Non-member - £420
SCI/RSC* Student member - £185

*RSC members should email their name, membership type and number to conferences@soci.org in order to receive the relevant code to book for this event.

All registrations will automatically receive a confirmation within 24 hours of registering for the event. Should you not receive written confirmation of your booking, please email conferences@soci.org.

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations


Booking Process/Deadlines

Booking terms and conditions


Sponsors

Exhibitors

Organising committee

Stuart Cameron, Concept Life Sciences
John Cumming, F Hoffmann-La Roche
Ray Finlay, AstraZeneca
Pascal Savy, Isomorphic Labs
Asier Unciti-Broceta, University of Edinburgh